PURPOSE: Provided is a novel variant strain which is prepared by mutagenesis of Aspergillus terrus CLS216-7, shows nystatine tolerance, mass-produces triol heptanoic acid, and minimizes the production of triol heptanoic acid analogue. And a method for manufacturing triol heptanoic acid using the same is also provided. CONSTITUTION: A novel variant strain, Aspergillus terrus CLS247-13(KCTC 0672BP), having high productability of triol heptanoic acid and nystatine tolerance is prepared by treating Aspergillus terrus CLS216-7(KCTC 0359BP) which has high productability of mevinolinic acid with UV or chemical mutagen. The variant strain is liquid pre-cultured in a shaking incubator at 28 deg.C and 230 rpm for 24-48 hours then liquid cultured for 10-15 days. The variant strain produces more than 11.5 g/L of triol heptanoic acid, shows nystatine tolerance, and minimizes the productability of triol hepanoic acid analogue to less than 0.53 goo/L. Wherein, the culture medium contains: a carbon source selected from the group consisting of lactose, dextrine, maltose, water soluble starch, starch, fructose, sucrose, xylose, glucose, galactose and glycerol; a nitrogen source selected from the group consisting of cornsteep liquor, dry yeast, peptone, casein, soy bean powder, ammonium sulfate, and ammonium nitrate and sodium nitrate; and inorganic materials such as Fe, Mg, Cu, B, Mo, Zn and so on.
展开▼
